Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab proof-of-concept study in non-cystic fibrosis bronchiectasis
CTR20242015Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of itepekimab in bronchiectasis, sponsored by Sanofi. Started Jun 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on CTR20242015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242015.